Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TYK2 | P29597 | 3/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21980552 | 1.00 | TLR7 (0.39) | TLR7MAPTNPSR1GAARAB9A | |
| SCHEMBL14726434 | 0.91 | GAA (0.44) | TLR7MAPTNPSR1GAARAB9A | |
| SCHEMBL14726546 | 0.90 | MAPT (0.37) | TLR7MAPTNPSR1GAARAB9A | |
| SCHEMBL14726578 | 0.89 | MAPT (0.42) | TLR7MAPTNPSR1GAARAB9A | |
| SCHEMBL10353528 | 0.88 | ITGB1 (0.43) | MAPTNPSR1GAARAB9AITGB1 | |
| SCHEMBL28993006 | 0.88 | ITGB1 (0.43) | MAPTNPSR1GAARAB9AITGB1 | |
| SCHEMBL29440976 | 0.88 | ITGB1 (0.43) | MAPTNPSR1GAARAB9AITGB1 | |
| SCHEMBL20061313 | 0.88 | ITGB1 (0.43) | MAPTNPSR1GAARAB9AITGB1 | |
| SCHEMBL14726516 | 0.87 | ITGB1 (0.42) | MAPTNPSR1GAARAB9AITGB1 | |
| SCHEMBL14726541 | 0.87 | ITGB1 (0.42) | MAPTNPSR1GAARAB9AITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-28 | — | — | US | disclosed |
| WO-2019028055-A1 | COMPOUNDS, COMPOSITIONALS, AND METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TLR7 3909/4885MAPT 1959/4885NPSR1 3184/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TLR7 3909/4885MAPT 1959/4885NPSR1 3184/4885 |
| US-11459306-B2 | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia | BCL9, BCL3, MCL1 | TLR7 2981/4885MAPT 4668/4885NPSR1 4762/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TLR7 3909/4885MAPT 1959/4885NPSR1 3184/4885 |
| US-20200165211-A1 | Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia | BCL9, BCL3, MCL1 | TLR7 2981/4885MAPT 4668/4885NPSR1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.